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Abstract: Background: Periodontitis has been associated to systemic diseases and this association
could be due to an increase in circulating inflammatory and oxidative stress biomarkers in the
periodontal disease. This study aimed to evaluate the relationship between inflammatory and pro-
oxidant markers according to different stages of periodontitis. Methods: This cross-sectional study
included 70 subjects who were divided into three groups according to periodontitis stage: stage II
(n = 22), stage III (n = 30), and stage IV (n = 18). We evaluated periodontal parameters and levels
of high-sensitivity C-reactive protein (hsCRP), fibrinogen, and malondialdehyde (MDA) in serum,
and 8-hydroxy-2′-deoxyguanosine (8-OHdG) in urine. Results: Serum hsCRP and fibrinogen levels
were associated with periodontitis severity, which were higher in stage IV than in stages III and II of
periodontitis (p = 0.003 and p = 0.025, respectively). We observed a slight yet insignificant increase
in MDA levels related to periodontitis severity. Probing depth and clinical attachment loss were
associated with serum fibrinogen and hsCRP levels. However, there were no significant associations
between periodontal variables and MDA and 8-OHdG levels. Conclusion: Our data support an
association between periodontitis and systemic inflammation, which increases with periodontal
disease severity. This indicates the importance of the early diagnosis and treatment of periodontal
disease to avoid the development or worsening of systemic inflammatory diseases.
Keywords: periodontal diseases; periodontitis; inflammation; 8-hydroxy-2′-deoxyguanosine; malon-
dialdehyde; oxidative stress
1. Introduction
Periodontitis is a very prevalent chronic disease that ranks sixth among the most
common pathologies that affect humans [1]. Recently, many publications have reported
that periodontitis is related to various systemic diseases, such as cardiovascular diseases [2].
Various systemic pathologies are linked to periodontitis through low-grade chronic inflam-
mation [3,4].
Acute phase reactants, such as high sensitivity C-reactive protein (hsCRP) and fib-
rinogen, are proteins whose plasma concentrations increase or decrease by at least 25%
during inflammatory processes [5]. These proteins are produced by the liver following the
stimulation of proinflammatory cytokines synthesised by endothelial cells. hsCRP levels
are used to determine serum CRP concentrations lower than 1 mg/dL to discriminate
small increases due to subclinical inflammatory processes [6]. Moreover, hsCRP is used to
assess cardiovascular risk [7]. Fibrinogen can increase between 2 and 20 times if there are
inflammatory processes [6].
Polymorphonuclear neutrophils, fundamental innate immune response cells, generate
proinflammatory cytokines, metalloproteinases, and reactive oxygen species (ROS), which
are crucial in the development and progression of periodontal damage [8]. Accordingly,
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malondialdehyde (MDA) is an organic compound resulting from the oxidation of polyun-
saturated fatty acids in cell membranes. MDA is generated when a hydroxide radical
interacts with lipids, captures a hydrogen atom from the methylene carbon, and causes
a very unstable lipid radical, which consequently reacts with another lipid and causes a
chain reaction leading to the formation of highly toxic aldehydes [9,10]. In the cell nucleus
and mitochondria, oxidative damage to DNA produces 8-hydroxy-2′-deoxyguanosine (8-
OHdG), which is a predominant form of deoxyguanosine resulting from guanine oxidation.
8-OHdG urine quantification estimates DNA damage caused by both endogenous and
exogenous agents [11].
Over the past few years, numerous clinical and basic experimental studies have shown
a strong association between oxidative stress and periodontitis, but most of these peri-
odontal studies evaluated total antioxidant capacity, total oxidant status, and oxidative
stress index [12]. However, other recent studies evaluated oxidative stress markers, such
as MDA and 8-OHdG levels, but mainly at the local level in saliva [13–16] and gingi-
val crevicular fluid [14,17] and only a few studies evaluated MDA and 8-OHdG levels
in serum [13,18,19]. Although these studies have different results, associations between
periodontitis and MDA and 8-OHdG levels have been observed [18–20]. Thus, the asso-
ciation between periodontitis and circulating oxidative stress biomarkers could indicate
that periodontitis could contribute to the development and progression of several systemic
inflammatory diseases [21], whether mitochondrial dysfunction is triggered due to an exac-
erbated inflammatory process [22]. Therefore, this study aimed to evaluate the relationship
between inflammatory and pro-oxidant markers according to different periodontitis stages
to determine whether an advanced stage of periodontitis could affect the systemic health
of patients.
2. Materials and Methods
2.1. Study Population
Study participants aged between 30 and 75 years were consecutively recruited at
our private dental clinic (Paterna, Valencia, Spain) between June 2019 and March 2020
for this cross-sectional study. Participants were diagnosed with periodontitis when an
interdental clinical attachment loss (CAL) in ≥2 non-adjacent teeth or a buccal or oral
CAL ≥3 mm with pocketing >3 mm in ≥2 teeth is detected according to the 2017 World
Workshop definition [23]. Exclusion criteria were fewer than 14 teeth, infectious or other
oral inflammatory diseases, comorbidities such as diabetes or obesity, receipt of periodontal
treatment in the last 6 months or antibiotics in the previous 3 months, being under systemic
anti-inflammatory treatment, pregnancy, lactation, severe disease including malignancies,
alcohol, or drug abuse. Data on smoking were recorded.
This human observational study was conducted according to Strengthening the Report-
ing of Observational Studies in Epidemiology (STROBE) guidelines and is in accordance
with the ethical principles stated in the Declaration of Helsinki. All procedures were ap-
proved by the ethics committee of the Arnau de Vilanova-Lliria (Valencia, Spain) hospital
(protocol RAM-LIG-2019-01), and all participants gave written informed consent.
2.2. Clinical Periodontal Determinations
Periodontal examinations were conducted by an experienced dentist (R. Andreu).
Periodontal assessments included measurements of probing depth (PD), CAL, number
of sites with PD ≥4 mm, percentage of sites with PD 1–3 mm, 4–5 mm, and ≥6 mm,
gingival bleeding on probing (BOP), and plaque index, which were recorded using a
manual periodontal probe PCP UNC-15 (Hu-Friedy, Chicago, IL, USA). PD, CAL, and
BOP were measured at six sites per tooth for all teeth, excluding third molars. PD was
measured as the distance between the gingival margin and the clinical pocket base, CAL
was recorded as the distance between the cemento–enamel junction and the clinical pocket
base, with both values expressed in millimetres, and the BOP percentage was calculated by
dividing the number of sites with BOP by the number of sites explored and multiplying
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this value by 100. We assessed the Silness and Löe simplified Plaque Index and scored it in
six representative Ramfjörd teeth: upper right first molar, upper left central incisor, upper
left first premolar, lower left first molar, lower right central incisor, and lower right first
premolar. Participants were classified according to three periodontitis stages according to
the 2017 World Workshop definition [23]. Subjects were classified as having stage II when
interdental CAL at site of greatest loss was 3 to 4 mm and maximum PD ≤ 5 mm, stage III
when CAL ≥ 5 mm, PD ≥ 6 mm and tooth loss due to periodontitis of ≤4 teeth, and stage
IV when CAL ≥ 5 mm, PD ≥ 6 mm and tooth loss due to periodontitis of ≥5 teeth.
2.3. Biochemical Determinations
Venous blood and urine samples were analysed at the Analclinic Laboratory (Mislata-
Valencia, Spain). Serum samples were obtained to measure hsCRP and fibrinogen levels
as inflammatory markers and acute phase reactants, and malondialdehyde (MDA) levels
as oxidative stress markers. Serum hsCRP levels (mg/dL) were quantified using an im-
munonephelometric assay (Dade Behring, Marburg, Germany), fibrinogen levels (mg/dL)
were obtained through the Coagulometry-Thrombin-Clauss time technique using a Solea
100 automatic analyser (Biolabo diagnostics, Maizy, France), and MDA levels (µmol/L)
were obtained by the Asakawa-Matsushita method by reacting MDA with 2-thiobarbituric
acid, giving a coloured MDA-TBA complex that is quantified using a Uvikon-810 spec-
trophotometer (Kontron Instruments, Augsburg, Germany). 8-OHdG levels (µg/g crea-
tinine) were tested from urine samples using high-performance liquid chromatography
(Analytical HPLC 1200 Series, Agilent Technologies, Santa Clara, CA, USA), which is also
an oxidative stress marker.
2.4. Statistical Analysis
In reference to sample size determination, the present study was designed in a finite
population. Thus, in our case, taking into account that the flow of patients during the
selection period can be estimated at 90 periodontal patients/year in the clinic, as well
as considering a power of 95% in order to be able to detect differences of ≥0.25 mg/dL
between the groups in relation to the primary efficacy criterion (serum hsCRP levels
variation), assuming a common standard deviation of 0.20 mg/dL and with an α risk of
0.05. Under these premises, at least 69 subjects were required.
Statistical analyses were performed using SPSS software (IBM Co., Armonk, NY, USA).
Continuous variables were expressed as mean and standard deviation for parametric data,
qualitative data were expressed as percentages, and proportions were compared using a chi-
square test. Continuous variables were compared among groups according to periodontitis
stages using a one-way analysis of variance or Kruskal–Wallis test, followed in each case
by a post-hoc test. Spearman’s correlation coefficient was used to evaluate the strength
of the association between periodontal, inflammatory, and oxidative stress variables. A
multivariable regression model was used to evaluate the relationship between two or
more explanatory variables, considered as independent variables, and a response variable,
considered as a dependent variable, using a stepwise method. A confidence interval of 95%
was determined for all tests and a p-value <0.05 was considered statistically significant.
3. Results
This cross-sectional study analysed 70 subjects with periodontitis. Of these subjects,
27 were men, and 43 were women. Participants were classified according to three peri-
odontitis stages; 22 subjects were classified as having stage II, 30 as having stage III, and 18
as having stage IV, according to the 2017 World Workshop definition [23].
Participant demographic and periodontal parameters are presented in Table 1. No
significant differences were found between groups regarding sex. Mean study population
age was 53.7 ± 9.3 years, and although the group with advanced periodontitis had a
slightly older age, no significant differences were observed between groups regarding
age (p = 0.055). Most patients in this study did not smoke (65.7%), and no differences
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were observed in the smoking rate among the three groups as assessed by a chi-square
test (p = 0.134). Regarding periodontal clinical parameters, PD and CAL progressively
worsened with periodontitis severity. Moreover, BOP and the number and percentage of
sites with periodontal pockets were higher in patients with stage III and IV periodontal
disease than in patients with stage II, whereas the percentage of healthy periodontal sites
(PD 1–3 mm) was higher in patients with stage II periodontitis than in patients with stage
III and IV. The plaque index was similar between groups (p = 0.554).
Table 1. Descriptive study population parameters according to periodontitis stages.
Periodontitis
Stage II Stage III Stage IV All
Demographic parameters
n (% females) 22 (21.4) 30 (24.3) 18 (15.7) 70 (61.4)
Age (years) 52.5 ± 10.4 51.9 ± 9.0 58.2 ± 7.2 53.7 ± 9.3
Smoking habit
Non-smokers % (n) 20.0 (14) 28.6 (20) 17.1 (12) 65.7 (46)
Smokers ≤10
cigarettes/day 10.0 (7) 4.3 (3) 2.9 (2) 17.1 (12)
Smokers >10
cigarettes/day 1.4 (1) 10.0 (7) 5.7 (4) 17.1 (12)
Periodontal parameters
PD (mm) 2.64 ± 0.35 a 3.51 ± 0.68 b 3.92 ± 0.65 c 3.34 ± 0.77 ***
CAL (mm) 2.80 ± 0.35 a 3.68 ± 0.65 b 4.16 ± 0.68 c 3.53 ± 0.78 ***
Sites PD ≥ 4 mm (n) 27.6 ± 18.8 a 68.6 ± 30.6 b 64.0 ± 23.6 b 54.5 ± 31.3 ***
Sites PD 1–3 mm (%) 82.7 ± 11.6 a 55.7 ± 19.2 b 47.6 ± 17.5 b 62.1 ± 21.9 ***
Sites PD 4–5 mm (%) 16.6 ± 11.8 a 31.7 ± 12.2 b 36.9 ± 11.6 b 28.3 ± 14.3 ***
Sites PD ≥ 6 mm (%) 1.07 ± 0.85 a 12.3 ± 10.6 b 15.6 ± 9.4 b 9.61 ± 10.2 ***
BOP (%) 21.4 ± 17.2 a 32.4 ± 21.3 a,b 44.4 ± 32.4 b 32.0 ± 24.8 **
Plaque index (A.U) 0.71 ± 0.75 0.72 ± 0.63 0.93 ± 0.91 0.77 ± 0.74
Notes: PD, probing depth; CAL, clinical attachment loss; BOP, bleeding on probing; and A.U, arbitrary units. Data are presented as
mean ± standard deviation or percentages (n). ** p < 0.01; and *** p < 0.001 when patients with different periodontitis stages were compared
with an analysis of variance test. Values with different superscript letters (a, b and c) were significantly different when the three groups were
compared using a Student–Newman–Keuls post-hoc test. Hence, means with the same superscript letters are not significantly different
(p > 0.05), while means that have no superscript letters in common are significantly different (p < 0.05).
To investigate whether proinflammatory and prooxidative parameters worsen with
periodontitis severity, we compared these variables among the three study groups ac-
cording to periodontitis stage (Figure 1). Systemic inflammatory markers, hsCRP, and
fibrinogen, considered as acute phase reactants, were significantly different between groups
(p = 0.003 and p = 0.025, respectively), with higher values in the advanced periodontitis
group (stage IV) (Figure 1A,B) than in the other two groups. Mean hsCRP in stage IV
0.463 ± 0.390 mg/dL vs. 0.224 ± 0.203 mg/dL in stage III and 0.210 ± 0.145 mg/dL in stage
II. Likewise, mean fibrinogen levels in stage IV 390.6 ± 68.8 mg/dL vs. 338.5 ± 76.5 mg/dL
in stage III and 332.2 ± 67.7 mg/dL in stage II. In addition, we determined prooxida-
tive parameter levels, including serum MDA levels and urine 8-OHdG levels. We ob-
served a slight and progressive yet insignificant increase in MDA levels as periodontitis
severity increased (0.66 ± 0.18 µmol/L in stage II; 0.71 ± 0.2 µmol/L in stage III; and
0.73 ± 0.26 µmol/L in stage IV. Figure 1C). Likewise, no differences were observed in
8-OHdG urine levels between groups (10.9 ± 3.05 µg/g in stage II; 9.17 ± 2.05 µg/g in
stage III; and 9.84 ± 3.21 µg/g in stage IV. Figure 1D).
Correlation coefficients between periodontal, inflammatory, and pro-oxidant parame-
ters from all population are shown in Table 2. PD and CAL, which are periodontal clinical
parameters that indicate disease and periodontitis severity, were positively correlated with
hsCRP (r = 0.216, p = 0.037; and r = 0.234, p = 0.026, respectively) and fibrinogen levels
(r = 0.320, p = 0.007; and r = 0.335, p = 0.002, respectively), suggesting a major inflammatory
periodontitis component. Moreover, fibrinogen was positively correlated with BOP and
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the percentage of sites with PD ≥ 6 mm and negatively correlated with the percentage of
sites with PD 1–3 mm. In addition, there was a correlation between both proinflammatory
parameters, hsCRP, and fibrinogen. Regarding oxidative stress parameters, no correla-
tions were observed between clinical periodontal parameters and serum MDA and urine
8-OHdG levels. However, when we studied bivariate correlations segmenting participants
by periodontitis stages, we observed a statistically significant positive correlation between
MDA and BOP in patients with stage II periodontitis (r = 0.707, and p = 0.025). Finally, we
detected bivariate correlations between all analysed periodontal parameters except the
plaque index, which was not significantly correlated with CAL and the percentage of sites
with PD ≥ 6 mm (data not shown).
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Figure 1. Study population inflammatory and oxidative stress parameters according to periodontitis stages. Serum high-
sensitivity C-reactive protein (A), fibrinogen (B) and malondialdehyde (C), and urine 8-hydroxy-2′-deoxyguanosine (D) lev-
els. Notes: hsCRP, high-sensitive C-reactive protein; MDA, malondialdehyde; and 8-OHdG, 8-hydroxy-2′-deoxyguanosine.
Data are presented as mean ± standard error. Values with different superscript letters (a and b) were significantly different
(p < 0.05) when the data of patients with different periodontitis stages were compared using a one-way analysis of variance
followed by a Student–Newman–Keuls post-hoc test. Hence, means with the same superscript letters are not significantly
different (p > 0.05), while me ns with no superscript lett rs in common are significantly differe t (p < 0.05).
Table 2. Spearman’s correlation coefficients between periodontal, inflammatory, and oxidative stress parameters.
hsCRP Fibrinogen MDA 8-OHdG
r p r p r p r p
PD 0.216 0.037 0.320 0.007 −0.245 0.183 −0.030 0.876
CAL 0.234 0.026 0.335 0.005 −0.229 0.214 −0.041 0.831
n Sites PD ≥ 4 mm 0.044 0.717 0.226 0.062 −0.142 0.445 −0.061 0.751
% Sites PD 1–3 mm −0.119 0.330 −0.264 0.028 0.190 0.305 0.076 0.695
% Sites PD 4–5 mm 0.113 0.353 0.231 0.056 0.009 0.960 0.025 0.898
% Sites PD ≥ 6 mm 0.188 0.121 0.263 0.029 −0.186 0.315 −0.032 0.869
% BoP 0.137 0.261 0.311 0.009 0.062 0.740 0.046 0.814
Plaque index 0.043 0.726 −0.057 0.644 0.237 0.199 −0.048 0.806
hsCRP —- —- 0.490 <0.001 0.191 0.302 −0.137 0.478
Fibrinogen 0.490 <0.001 —- —- −0.098 0.605 −0.204 0.290
MDA 0.191 0.302 −0.098 0.605 —- —- 0.244 0.202
8-OHdG −0.137 0.978 −0.204 0.290 0.244 0.202 —- —-
Notes: PD, probing depth; CAL, clinical attachment loss; BOP, bleeding of probing; hsCRP, high-sensitivity C-reactiv protein; MDA,
malondialdehyde; and 8-OHdG, 8-hydroxy-2′-deoxyguanosine. Values in bold represent statistically significant correlations (p < 0.05).
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As fibrinogen showed significant correlations with several periodontal parameters,
we aimed to analyse these associations using a multivariate linear regression analysis. In
the multivariable regression model, the association between fibrinogen and correlated
variables was evaluated as a potentially independent predictor using the stepwise method.
Results showed that hsCRP (β = 0.441) and CAL (β = 0.280) were independently associated
with fibrinogen serum levels; this explained 30% of the dependent variable (Table 3).








Fibrinogen hsCRP 11.96 2.83 0.441 <0.001
CAL 26.14 9.74 0.280 0.009
Multiple R square adjusted 0.304
R 0.570
p <0.001
PD, BOP, percentage of sites with PD 1–3 mm, and PD ≥ 6 mm were excluded from the model because they were not significant predictors
(p > 0.05). Notes: hsCRP, high-sensitivity C-reactive protein; CAL, clinical attachment loss; PD, probing depth; and BOP, bleeding
on probing.
4. Discussion
This study has demonstrated that serum hsCRP and fibrinogen levels are associated
with periodontal disease and both parameters increase with periodontitis severity. In this
study, we observed a slight and progressive yet insignificant increase in MDA levels as pe-
riodontitis severity increased. Likewise, we did not find associations between periodontal
parameters and systemic MDA and 8-OHdG levels.
Previous studies suggested a multidirectional association between periodontitis and
inflammatory systemic diseases [24]; thus, patients with periodontitis are at greater risk
of developing and/or exacerbating diabetes, chronic obstructive pulmonary disease, and
cardiovascular diseases, among other conditions [25]. However, these associations re-
main controversial.
Several epidemiological studies have reported that periodontitis is related to arte-
riosclerotic events, and this association has been suggested due to the increase in serum
levels of proinflammatory and pro-oxidant markers in both diseases, such as TNFα, IL-1,
IL-6, and CRP [26–29], fibrinogen [30], MDA [18,25], and 8-OHdG [13,31]. Recently, a study
has even shown that periodontitis-especially severe-is independently associated with a con-
siderable increase in platelet count due to an increase in the systemic inflammation, which
could be a new potential link with cardiovascular disease [32]. On the contrary, some stud-
ies suggest that this association is mainly due to the existence of common risk factors [33,34].
Some studies only observed an increase in hsCRP levels in some individuals with periodon-
titis [33], and in other studies, it has been observed that patients with periodontitis showed
similar levels of hsCRP in serum compared to edentulous individuals [34]. However, a
large number of previous epidemiological studies have shown an association between peri-
odontal and proinflammatory parameters [26–30,35,36], suggesting the possible systemic
repercussions that local chronic inflammation could increase the systemic inflammatory
burden. In addition, previous studies have shown that non-surgical periodontal therapy
was effective in reducing the plasma levels of hsCRP and fibrinogen [37,38]. In line with
these findings, in this study, we observed that both serum hsCRP and fibrinogen increased
with periodontitis severity. Furthermore, we observed positive associations between pe-
riodontal clinical parameters and both inflammatory parameters, especially fibrinogen.
When we applied the stepwise method with fibrinogen as the dependent variable and all
variables correlated with fibrinogen as independent variables, we observed a significant
relationship between hsCRP and CAL, showing the interconnection between different
systemic inflammation markers and probing dependent variables with a cumulative profile.
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Therefore, we suggest that determining serum hsCRP and fibrinogen levels in patients
with periodontitis, especially in those with stage III or IV of periodontitis, can be very
useful for predicting cardiovascular results. hsCRP is very useful as it represents a global
measure of endothelial function [39], and fibrinogen strongly affects blood coagulation,
blood rheology, and platelet aggregation and directly affects the vascular wall. All these
phenomena might constitute the pathophysiological mechanisms involved in the associa-
tion between these prominent acute-phase reactants and cardiovascular events [40]. Thus,
a possible mechanism potentially linking periodontitis to atherosclerosis is the dumping
of inflammatory mediators originating from periodontal lesions into systemic circulation.
Such inflammatory mediators, including CRP, matrix metalloproteinases, fibrinogen, and
other haemostatic factors, may further accelerate atheroma formation and progression
mainly through oxidative stress and inflammatory dysfunction [41].
Most previous periodontal studies evaluated oxidative stress through the global bur-
den of ROS and guanine-derived biomarkers in saliva and gingival crevicular fluid [42–44].
However, in this current study, we evaluated fluctuations in both markers in blood and
urine; these fluctuations are more commonly related to systemic oxidative damage markers
associated with periodontal diseases, such as MDA and 8-OHdG [13,18,19,45–48].
In a recent meta-analysis, most studies on periodontitis and oxidative stress found a
significant increase in MDA levels in the saliva and gingival crevicular fluid of patients
with periodontitis compared to non-periodontitis patients [14]. However, in this systematic
review, no data on serum MDA levels were collected. In this study, we evaluated MDA
levels in serum samples. Although we did not observe statistically significant differences
in serum MDA levels among groups with different periodontitis stages, a slight increase
in MDA levels can be seen as periodontitis severity increases. Nonetheless, we did not
observe significant correlations between periodontal parameters and serum MDA levels.
Similar to our study, a previous study did not observe an association between periodon-
titis and serum MDA levels, although it showed higher saliva MDA levels in patients
with periodontitis and a significant correlation between these saliva MDA levels and pe-
riodontal parameters [49]. The lack of an association between serum MDA levels and
periodontal parameters in this study may be because this oxidative stress parameter was
evaluated in a small representative study population sample. Nevertheless, it is worthy to
note that a surprising association was found between MDA and BOP when a correlation
analysis segmenting the population by stages of periodontitis was performed. Similar
to this result, BOP showed a moderate positive correlation with serum MDA levels in a
previous study [50]. Gingival bleeding on probing is a sign of local inflammation and peri-
odontal destruction, which can increase proinflammatory marker and oxidative damage
systemic levels.
The most frequent oxidative DNA modification usually occurs at guanosine levels,
producing 8-OHdG. 8-OHdG levels were used as an index of oxidative DNA damage.
Recently, 8-OHdG has been widely used in many studies not only as a biomarker for mea-
suring endogenous oxidative DNA damage, but also as a risk factor for many diseases [48].
Previous studies have detected higher salivary 8-OHdG levels in periodontitis patients
than in healthy controls [51] and also significant correlations between salivary 8-OHdG
levels and periodontal parameters [20]. In other studies, higher serum 8-OHdG levels have
been observed in patients with periodontitis and hyperlipidemia [52], or periodontitis and
polycystic ovary syndrome [19] than in patients without periodontal disease associated
with systemic pathology. In addition, a recent systematic review with meta-analysis
identified increased levels of 8-OHdG in gingival crevicular fluid of periodontitis sites [53].
However, unlike this study, previous studies have not evaluated the urine 8-OHdG levels
in patients with periodontitis. We did not observe significant differences in urine 8-OHdG
levels between patients with different periodontitis stages. Likewise, we did not observe a
significant correlation between urine 8-OHdG levels and periodontal clinical parameters.
After DNA repair, 8-OHdG is excreted in the urine, and numerous studies have indicated
that urinary 8-OHdG is an important cellular oxidative stress biomarker [48]. Therefore,
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more studies on patients with periodontitis are required to evaluate systemic blood or
urine oxidative stress markers to determine the impact of periodontal disease on the
pathophysiology of systemic inflammatory diseases.
To the best of our knowledge, this is the first periodontal study to measure urine
8-OHdG levels to determine the effect of periodontitis on systemic pro-oxidant marker
levels. We performed a full-mouth periodontal examination, measuring six sites per
tooth for all teeth, thus obtaining more comprehensive data than studies using a partial
mouth assessment. However, this study has some limitations. The sample size was small.
Therefore, when dividing the sample by periodontitis stages, the groups could individually
lose statistical power. MDA and 8-OHdG levels were evaluated only in serum and urine
samples, respectively. The grade criterion was not used to classify the groups due to the
small sample size and the cross-sectional nature of the study. Finally, the cross-sectional
nature of this study limits its interpretability. Undoubtedly, there is still much to learn
about the association between systemic proinflammatory and pro-oxidant markers and
periodontitis and their relationship with systemic inflammatory disease risk. Further
prospective studies should be conducted to further reveal the role of periodontitis on
systemic levels of inflammatory and pro-oxidant markers and their respective consequences
on general health.
5. Conclusions
The findings of this study support the concept that periodontitis, especially advanced
periodontitis, increases systemic inflammation mediators’ levels, which are atherosclerotic
disease risk factors. We observed an increase in serum of hsCRP and fibrinogen levels as
the severity of periodontitis increases. However, we did not find associations between
periodontitis severity and MDA serum levels and 8-OHdG urine levels. This suggests
the importance of early periodontal diagnosis and treatment to avoid possible future
systemic complications due to the persistence of chronic inflammation. Periodontitis, as
a local inflammatory disease, could cause an increase in inflammation and consequently
in systemic oxidative stress and could be involved in the development or exacerbation
of systemic inflammatory diseases, such as cardiovascular disease. Therefore, further
prospective studies are needed to evaluate the systemic oxidative stress marker levels
in patients with periodontitis to establish possible implications of periodontal disease in
systemic inflammatory diseases.
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